D56.8 – Other Thalassaemias: Causes & Treatment
D56.8 is the ICD-10 code for other thalassaemias – inherited blood disorders causing impaired haemoglobin production and haemolytic anaemia requiring medical evaluation.
Things worth knowing about "D56.8"
D56.8 is the ICD-10 code for other thalassaemias – inherited blood disorders causing impaired haemoglobin production and haemolytic anaemia requiring medical evaluation.
What is D56.8 – Other Thalassæmias?
The ICD-10 code D56.8 refers to other thalassæmias – forms of thalassæmia that do not fall under the more specifically coded subtypes such as alpha- or beta-thalassæmia. Thalassæmias are inherited blood disorders in which the production of haemoglobin – the oxygen-carrying protein in red blood cells – is impaired. This leads to a shortened lifespan of red blood cells and results in haemolytic anaemia, a form of anaemia caused by the premature breakdown of red blood cells.
Causes
Thalassæmias are caused by mutations in the genes responsible for synthesising the globin chains that make up haemoglobin. Depending on which chains are affected, different forms of the disorder arise.
- Mutations are typically inherited in an autosomal recessive pattern.
- A person may carry one or two mutated copies of the relevant gene.
- D56.8 encompasses rare or combined globin chain mutations that do not match a classical alpha- or beta-thalassæmia pattern.
Symptoms
The severity of symptoms depends on the type and extent of the genetic alteration. Common signs and symptoms include:
- Anaemia: Fatigue, weakness, and pallor
- Enlarged spleen and liver (hepatosplenomegaly)
- Delayed growth and development in children
- Bone pain and bone marrow changes
- Increased susceptibility to infections
- Jaundice (icterus) due to increased haemoglobin breakdown
Diagnosis
Diagnosis is established through a combination of clinical assessment and laboratory investigations:
- Complete blood count (CBC): Reveals anaemia with characteristically small, pale red blood cells (microcytic, hypochromic anaemia)
- Haemoglobin electrophoresis: Analyses the different forms of haemoglobin present
- Molecular genetic testing: Identifies the specific gene mutation
- Family history: Assessment of the medical background of parents and siblings
Treatment
Treatment depends on the severity of the condition:
- Mild forms (thalassæmia minor): Often require little or no treatment; regular monitoring is recommended.
- Moderate to severe forms: Regular blood transfusions to maintain adequate haemoglobin levels.
- Chelation therapy: Used to manage iron overload resulting from frequent transfusions.
- Bone marrow transplantation (allogeneic stem cell transplantation): A potentially curative option for eligible patients.
- Folic acid supplementation: Supports red blood cell production.
- Gene therapy: Novel approaches are currently under clinical investigation.
Prognosis and Disease Course
The prognosis depends strongly on the specific mutation and the severity of the disease. Mild forms are generally associated with a normal life expectancy. Severe forms require consistent, lifelong management. With modern therapies, the quality of life for affected patients has improved significantly over recent decades.
References
- World Health Organization (WHO): Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO/NMH/NHD/MNM/11.1. Geneva, 2011.
- Galanello R, Origa R. Beta-thalassemia. Orphanet Journal of Rare Diseases. 2010;5:11. DOI: 10.1186/1750-1172-5-11.
- Weatherall DJ. The inherited diseases of haemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336. DOI: 10.1182/blood-2010-01-251348.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.